Prolactin gene polymorphism (- 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics

Bibliographic Details
Parent link:Schizophrenia Research
Vol. 182.— 2017.— [P. 110–114]
Corporate Author: Национальный исследовательский Томский политехнический университет (ТПУ) Институт неразрушающего контроля (ИНК) Кафедра экологии и безопасности жизнедеятельности (ЭБЖ)
Other Authors: Ivanova S. A. Svetlana Aleksandrovna, Osmanova D. Z. Diana, Boyko A. S. Anastasiya Sergeevna, Pozhidaev I. V. Ivan, Freydin M. V., Fedorenko O. Yu. Olga Yurievna, Semke A. V. Arkady Valentinovich, Bokhan N. A. Nikolay Aleksandrovich, Kornetova E. G. Elena Georgievna, Rakhmazova L. D. Lyubov Demjyanovna, Vilffert B. Bob, Loonen A. J. M. Anton
Summary:Title screen
Background: Antipsychotic drugs can cause hyperprolactinemia. However, hyperprolactinemia was also observed in treatment-naive patients with a first schizophrenic episode. This phenomenon might be related to the role of prolactin as a cytokine in autoimmune diseases. Extrapituitary prolactin production is regulated by an alternative promoter, which contains the functional single nucleotide polymorphism −1149 G/T (rs1341239). We examined whether this polymorphism was associated with hyperprolactinemia in patients with schizophrenia. Method: We recruited 443 patients with schizophrenia and 126 healthy controls. The functional polymorphism −1149 G/T (rs1341239) in the prolactin gene was genotyped with multiplexed primer extension, combined with MALDI-TOF mass spectrometry. Genotype and allele frequencies were compared between groups with the χ2 test and logistic regression models adjusting for covariates. Results: The frequency of genotypes and alleles in patients with schizophrenia did not differ from those in control subjects. A comparison between patients with schizophrenia with and without hyperprolactinemia revealed significantly higher frequency of the G allele in patients with hyperprolactinemia than in patients without it (χ2 = 7.25; p = 0.007; OR = 1.44 [1.10-1.89]). Accordingly, patients with hyperprolactinemia carried the GG genotype more frequently than patients without hyperprolactinemia (χ2 = 9.49; p = 0.009). This association remained significant after adjusting the estimates for such covariates as sex, age, duration of the diseases and the dose of chlorpromazine equivalents. Conclusion: This study revealed a significant association between the polymorphic variant rs1341239 and the development of hyperprolactinemia in patients with schizophrenia. The serum prolactin concentration in patients with schizophrenia treated with antipsychotics may provide an indication of the activity of the gene that regulates extrapituitary prolactin production which is believed to play a role in the immune system.
Режим доступа: по договору с организацией-держателем ресурса
Language:English
Published: 2017
Subjects:
Online Access:http://doi.org/10.1016/j.schres.2016.10.029
Format: Electronic Book Chapter
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=654147

MARC

LEADER 00000naa0a2200000 4500
001 654147
005 20250310164400.0
035 |a (RuTPU)RU\TPU\network\19674 
035 |a RU\TPU\network\19634 
090 |a 654147 
100 |a 20170413d2017 k||y0rusy50 ba 
101 0 |a eng 
135 |a drcn ---uucaa 
181 0 |a i  
182 0 |a b 
200 1 |a Prolactin gene polymorphism (- 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics  |f S. A. Ivanova [et al.] 
203 |a Text  |c electronic 
300 |a Title screen 
320 |a [References: 33 tit.] 
330 |a Background: Antipsychotic drugs can cause hyperprolactinemia. However, hyperprolactinemia was also observed in treatment-naive patients with a first schizophrenic episode. This phenomenon might be related to the role of prolactin as a cytokine in autoimmune diseases. Extrapituitary prolactin production is regulated by an alternative promoter, which contains the functional single nucleotide polymorphism −1149 G/T (rs1341239). We examined whether this polymorphism was associated with hyperprolactinemia in patients with schizophrenia. Method: We recruited 443 patients with schizophrenia and 126 healthy controls. The functional polymorphism −1149 G/T (rs1341239) in the prolactin gene was genotyped with multiplexed primer extension, combined with MALDI-TOF mass spectrometry. Genotype and allele frequencies were compared between groups with the χ2 test and logistic regression models adjusting for covariates. Results: The frequency of genotypes and alleles in patients with schizophrenia did not differ from those in control subjects. A comparison between patients with schizophrenia with and without hyperprolactinemia revealed significantly higher frequency of the G allele in patients with hyperprolactinemia than in patients without it (χ2 = 7.25; p = 0.007; OR = 1.44 [1.10-1.89]). Accordingly, patients with hyperprolactinemia carried the GG genotype more frequently than patients without hyperprolactinemia (χ2 = 9.49; p = 0.009). This association remained significant after adjusting the estimates for such covariates as sex, age, duration of the diseases and the dose of chlorpromazine equivalents. Conclusion: This study revealed a significant association between the polymorphic variant rs1341239 and the development of hyperprolactinemia in patients with schizophrenia. The serum prolactin concentration in patients with schizophrenia treated with antipsychotics may provide an indication of the activity of the gene that regulates extrapituitary prolactin production which is believed to play a role in the immune system. 
333 |a Режим доступа: по договору с организацией-держателем ресурса 
461 |t Schizophrenia Research 
463 |t Vol. 182  |v [P. 110–114]  |d 2017 
610 1 |a электронный ресурс 
610 1 |a труды учёных ТПУ 
610 1 |a cytokines 
610 1 |a hyperprolactinemia 
610 1 |a цитокины 
610 1 |a полиморфизм 
610 1 |a шизофрения 
701 1 |a Ivanova  |b S. A.  |c specialist in the field of ecology and life safety  |c Professor of Tomsk Polytechnic University, doctor of medical sciences  |f 1964-  |g Svetlana Aleksandrovna  |3 (RuTPU)RU\TPU\pers\33859 
701 1 |a Osmanova  |b D. Z.  |g Diana 
701 1 |a Boyko  |b A. S.  |g Anastasiya Sergeevna 
701 1 |a Pozhidaev  |b I. V.  |g Ivan 
701 1 |a Freydin  |b M. V. 
701 1 |a Fedorenko  |b O. Yu.  |c specialist in the field of ecology and life safety  |c Professor of Tomsk Polytechnic University, doctor of medical sciences  |f 1973-  |g Olga Yurievna  |3 (RuTPU)RU\TPU\pers\33861  |9 17450 
701 1 |a Semke  |b A. V.  |g Arkady Valentinovich 
701 1 |a Bokhan  |b N. A.  |g Nikolay Aleksandrovich 
701 1 |a Kornetova  |b E. G.  |g Elena Georgievna 
701 1 |a Rakhmazova  |b L. D.  |g Lyubov Demjyanovna 
701 1 |a Vilffert  |b B.  |g Bob 
701 1 |a Loonen  |b A. J. M.  |g Anton 
712 0 2 |a Национальный исследовательский Томский политехнический университет (ТПУ)  |b Институт неразрушающего контроля (ИНК)  |b Кафедра экологии и безопасности жизнедеятельности (ЭБЖ)  |3 (RuTPU)RU\TPU\col\18720 
801 2 |a RU  |b 63413507  |c 20170413  |g RCR 
856 4 |u http://doi.org/10.1016/j.schres.2016.10.029 
942 |c CF